Skip to main content
Top
Published in: EJNMMI Research 1/2021

Open Access 01-12-2021 | Metastasis | Original research

N-staging in large cell neuroendocrine carcinoma of the lung: diagnostic value of [18F]FDG PET/CT compared to the histopathology reference standard

Authors: Hubertus Hautzel, Yazan Alnajdawi, Wolfgang P. Fendler, Christoph Rischpler, Kaid Darwiche, Wilfried E. Eberhardt, Lale Umutlu, Dirk Theegarten, Martin Stuschke, Martin Schuler, Clemens Aigner, Ken Herrmann, Till Plönes

Published in: EJNMMI Research | Issue 1/2021

Login to get access

Abstract

Background

Large cell neuroendocrine carcinoma of the lung (LCNEC) is a rare entity occurring in less than 4% of all lung cancers. Due to its low differentiation and high glucose transporter 1 (GLUT1) expression, LCNEC demonstrates an increased glucose turnover. Thus, PET/CT with 2-[18F]-fluoro-deoxyglucose ([18F]FDG) is suitable for LCNEC staging. Surgery with curative intent is the treatment of choice in early stage LCNEC. Prerequisite for this is correct lymph node staging. This study aimed at evaluating the diagnostic performance of [18F]FDG PET/CT validated by histopathology following surgical resection or mediastinoscopy. N-staging interrater-reliability was assessed to test for robustness of the [18F]FDG PET/CT findings.

Methods

Between 03/2014 and 12/2020, 46 patients with LCNEC were included in this single center retrospective analysis. All underwent [18F]FDG PET/CT for pre-operative staging and subsequently either surgery (n = 38) or mediastinoscopy (n = 8). Regarding the lymph node involvement, sensitivity, specificity, accuracy, positive predictive value (PPV) and negative predictive value (NPV) were calculated for [18F]FDG PET/CT using the final histopathological N-staging (pN0 to pN3) as reference.

Results

Per patient 14 ± 7 (range 4–32) lymph nodes were resected and histologically processed. 31/46 patients had no LCNEC spread into the lymph nodes. In 8/46 patients, the final stage was pN1, in 5/46 pN2 and in 2/46 pN3. [18F]FDG PET/CT diagnosed lymph node metastasis of LCNEC with a sensitivity of 93%, a specificity of 87%, an accuracy of 89%, a PPV of 78% and a NPV of 96%. In the four false positive cases, the [18F]FDG uptake of the lymph nodes was 33 to 67% less in comparison with that of the respective LCNEC primary. Interrater-reliability was high with a strong level of agreement (κ = 0.82).

Conclusions

In LCNEC N-staging with [18F]FDG PET/CT demonstrates both high sensitivity and specificity, an excellent NPV but a slightly reduced PPV. Accordingly, preoperative invasive mediastinal staging may be omitted in cases with cN0 disease by [18F]FDG PET/CT. In [18F]FDG PET/CT cN1-cN3 stages histological confirmation is warranted, particularly in case of only moderate [18F]FDG uptake as compared to the LCNEC primary.
Literature
1.
go back to reference Gu J, Gong D, Wang Y, Chi B, Zhang J, Hu S, et al. The demographic and treatment options for patients with large cell neuroendocrine carcinoma of the lung. Cancer Med. 2019;8:2979–93.CrossRef Gu J, Gong D, Wang Y, Chi B, Zhang J, Hu S, et al. The demographic and treatment options for patients with large cell neuroendocrine carcinoma of the lung. Cancer Med. 2019;8:2979–93.CrossRef
2.
go back to reference Iyoda A, Makino T, Koezuka S, Otsuka H, Hata Y. Treatment options for patients with large cell neuroendocrine carcinoma of the lung. Gen Thorac Cardiovasc Surg. 2014;62:351–6.CrossRef Iyoda A, Makino T, Koezuka S, Otsuka H, Hata Y. Treatment options for patients with large cell neuroendocrine carcinoma of the lung. Gen Thorac Cardiovasc Surg. 2014;62:351–6.CrossRef
3.
go back to reference Lo Russo G, Pusceddu S, Proto C, Macerelli M, Signorelli D, Vitali M, et al. Treatment of lung large cell neuroendocrine carcinoma. Tumour Biol J Int Soc Oncodevelopmental Biol Med. 2016;37:7047–57.CrossRef Lo Russo G, Pusceddu S, Proto C, Macerelli M, Signorelli D, Vitali M, et al. Treatment of lung large cell neuroendocrine carcinoma. Tumour Biol J Int Soc Oncodevelopmental Biol Med. 2016;37:7047–57.CrossRef
4.
go back to reference Raman V, Jawitz OK, Yang C-FJ, Voigt SL, Tong BC, D’Amico TA, et al. Outcomes for surgery in large cell lung neuroendocrine cancer. J Thorac Oncol. 2019;14:2143–51.CrossRef Raman V, Jawitz OK, Yang C-FJ, Voigt SL, Tong BC, D’Amico TA, et al. Outcomes for surgery in large cell lung neuroendocrine cancer. J Thorac Oncol. 2019;14:2143–51.CrossRef
5.
go back to reference Kaira K, Murakami H, Endo M, Ohde Y, Naito T, Kondo H, et al. Biological correlation of 18F-FDG uptake on PET in pulmonary neuroendocrine tumors. Anticancer Res. 2013;33:4219–28.PubMed Kaira K, Murakami H, Endo M, Ohde Y, Naito T, Kondo H, et al. Biological correlation of 18F-FDG uptake on PET in pulmonary neuroendocrine tumors. Anticancer Res. 2013;33:4219–28.PubMed
6.
go back to reference Chong S, Lee KS, Kim B-T, Choi JY, Yi CA, Chung MJ, et al. Integrated PET/CT of pulmonary neuroendocrine tumors: diagnostic and prognostic implications. AJR Am J Roentgenol. 2007;188:1223–31.CrossRef Chong S, Lee KS, Kim B-T, Choi JY, Yi CA, Chung MJ, et al. Integrated PET/CT of pulmonary neuroendocrine tumors: diagnostic and prognostic implications. AJR Am J Roentgenol. 2007;188:1223–31.CrossRef
7.
go back to reference Song YS, Lee WW, Chung JH, Park SY, Kim YK, Kim SE. Correlation between FDG uptake and glucose transporter type 1 expression in neuroendocrine tumors of the lung. Lung Cancer. 2008;61:54–60.CrossRef Song YS, Lee WW, Chung JH, Park SY, Kim YK, Kim SE. Correlation between FDG uptake and glucose transporter type 1 expression in neuroendocrine tumors of the lung. Lung Cancer. 2008;61:54–60.CrossRef
8.
go back to reference Lee KW, Lee Y, Oh SW, Jin KN, Goo JM. Large cell neuroendocrine carcinoma of the lung: CT and FDG PET findings. Eur J Radiol. 2015;84:2332–8.CrossRef Lee KW, Lee Y, Oh SW, Jin KN, Goo JM. Large cell neuroendocrine carcinoma of the lung: CT and FDG PET findings. Eur J Radiol. 2015;84:2332–8.CrossRef
9.
go back to reference Eichhorn F, Dienemann H, Muley T, Warth A, Hoffmann H. Predictors of survival after operation among patients with large cell neuroendocrine carcinoma of the lung. Ann Thorac Surg. 2015;99:983–9.CrossRef Eichhorn F, Dienemann H, Muley T, Warth A, Hoffmann H. Predictors of survival after operation among patients with large cell neuroendocrine carcinoma of the lung. Ann Thorac Surg. 2015;99:983–9.CrossRef
10.
go back to reference Goldstraw P, Chansky K, Crowley J, Rami-Porta R, Asamura H, Eberhardt WEE, et al. The IASLC Lung Cancer Staging Project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer. J Thorac Oncol. 2016;11:39–51.CrossRef Goldstraw P, Chansky K, Crowley J, Rami-Porta R, Asamura H, Eberhardt WEE, et al. The IASLC Lung Cancer Staging Project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer. J Thorac Oncol. 2016;11:39–51.CrossRef
11.
go back to reference Detterbeck FC, Boffa DJ, Tanoue LT. The new lung cancer staging system. Chest. 2009;136:260–71.CrossRef Detterbeck FC, Boffa DJ, Tanoue LT. The new lung cancer staging system. Chest. 2009;136:260–71.CrossRef
12.
go back to reference Glazer GM, Gross BH, Quint LE, Francis IR, Bookstein FL, Orringer MB. Normal mediastinal lymph nodes: number and size according to American Thoracic Society mapping. AJR Am J Roentgenol. 1985;144:261–5.CrossRef Glazer GM, Gross BH, Quint LE, Francis IR, Bookstein FL, Orringer MB. Normal mediastinal lymph nodes: number and size according to American Thoracic Society mapping. AJR Am J Roentgenol. 1985;144:261–5.CrossRef
13.
go back to reference McHugh ML. Interrater reliability: the kappa statistic. Biochem Med. 2012;22:276–82.CrossRef McHugh ML. Interrater reliability: the kappa statistic. Biochem Med. 2012;22:276–82.CrossRef
14.
go back to reference Lococo F, Cesario A, Paci M, Filice A, Versari A, Rapicetta C, et al. PET/CT assessment of neuroendocrine tumors of the lung with special emphasis on bronchial carcinoids. Tumour Biol J Int Soc Oncodevelopmental Biol Med. 2014;35:8369–77.CrossRef Lococo F, Cesario A, Paci M, Filice A, Versari A, Rapicetta C, et al. PET/CT assessment of neuroendocrine tumors of the lung with special emphasis on bronchial carcinoids. Tumour Biol J Int Soc Oncodevelopmental Biol Med. 2014;35:8369–77.CrossRef
15.
go back to reference Grøndahl V, Binderup T, Langer SW, Petersen RH, Nielsen K, Kjaer A, et al. Characteristics of 252 patients with bronchopulmonary neuroendocrine tumours treated at the Copenhagen NET Centre of Excellence. Lung Cancer. 2019;132:141–9.CrossRef Grøndahl V, Binderup T, Langer SW, Petersen RH, Nielsen K, Kjaer A, et al. Characteristics of 252 patients with bronchopulmonary neuroendocrine tumours treated at the Copenhagen NET Centre of Excellence. Lung Cancer. 2019;132:141–9.CrossRef
16.
go back to reference Casali C, Cucca M, Rossi G, Barbieri F, Iacuzio L, Bagni B, et al. The variation of prognostic significance of Maximum Standardized Uptake Value of [18F]-fluoro-2-deoxy-glucose positron emission tomography in different histological subtypes and pathological stages of surgically resected Non-Small Cell Lung Carcinoma. Lung Cancer. 2010;69:187–93.CrossRef Casali C, Cucca M, Rossi G, Barbieri F, Iacuzio L, Bagni B, et al. The variation of prognostic significance of Maximum Standardized Uptake Value of [18F]-fluoro-2-deoxy-glucose positron emission tomography in different histological subtypes and pathological stages of surgically resected Non-Small Cell Lung Carcinoma. Lung Cancer. 2010;69:187–93.CrossRef
17.
go back to reference Agarwal M, Brahmanday G, Bajaj SK, Ravikrishnan KP, Wong CYO. Revisiting the prognostic value of preoperative (18)F-fluoro-2-deoxyglucose ( (18)F-FDG) positron emission tomography (PET) in early-stage (I & II) non-small cell lung cancers (NSCLC). Eur J Nucl Med Mol Imaging. 2010;37:691–8.CrossRef Agarwal M, Brahmanday G, Bajaj SK, Ravikrishnan KP, Wong CYO. Revisiting the prognostic value of preoperative (18)F-fluoro-2-deoxyglucose ( (18)F-FDG) positron emission tomography (PET) in early-stage (I & II) non-small cell lung cancers (NSCLC). Eur J Nucl Med Mol Imaging. 2010;37:691–8.CrossRef
18.
go back to reference Yamamoto T, Sakairi Y, Nakajima T, Suzuki H, Tagawa T, Iwata T, et al. Comparison between endobronchial ultrasound-guided transbronchial needle aspiration and 18F-fluorodeoxyglucose positron emission tomography in the diagnosis of postoperative nodal recurrence in patients with lung cancer. Eur J Cardio-Thoracic Surg. 2015;47:234–8.CrossRef Yamamoto T, Sakairi Y, Nakajima T, Suzuki H, Tagawa T, Iwata T, et al. Comparison between endobronchial ultrasound-guided transbronchial needle aspiration and 18F-fluorodeoxyglucose positron emission tomography in the diagnosis of postoperative nodal recurrence in patients with lung cancer. Eur J Cardio-Thoracic Surg. 2015;47:234–8.CrossRef
19.
go back to reference Kwon SY, Min J-J, Song H-C, Choi C, Na K-J, Bom H-S. Impact of lymphoid follicles and histiocytes on the False-Positive FDG uptake of lymph nodes in non-small cell lung cancer. Nucl Med Mol Imaging. 2010;2011(45):185–91. Kwon SY, Min J-J, Song H-C, Choi C, Na K-J, Bom H-S. Impact of lymphoid follicles and histiocytes on the False-Positive FDG uptake of lymph nodes in non-small cell lung cancer. Nucl Med Mol Imaging. 2010;2011(45):185–91.
20.
go back to reference Gedik GK, Yilmaz F. Is there any improvement in clinical staging with (18)F-FDG PET/CT compared to surgical staging in cases of lung cancer? Rev Esp Med Nucl Imagen Mol. 2019;38:348–54.PubMed Gedik GK, Yilmaz F. Is there any improvement in clinical staging with (18)F-FDG PET/CT compared to surgical staging in cases of lung cancer? Rev Esp Med Nucl Imagen Mol. 2019;38:348–54.PubMed
21.
go back to reference de Castro ABG, Ferreirós Domínguez J, Delgado Bolton R, Fernández Pérez C, Cabeza Martínez B, García-García-Esquinas M, et al. PET-CT in presurgical lymph node staging in non-small cell lung cancer: the importance of false-negative and false-positive findings. Radiologia. 2017;59:147–58.CrossRef de Castro ABG, Ferreirós Domínguez J, Delgado Bolton R, Fernández Pérez C, Cabeza Martínez B, García-García-Esquinas M, et al. PET-CT in presurgical lymph node staging in non-small cell lung cancer: the importance of false-negative and false-positive findings. Radiologia. 2017;59:147–58.CrossRef
22.
go back to reference Darling GE. Lymph node assessment in early stage non-small cell lung cancer lymph node dissection or sampling? Gen Thorac Cardiovasc Surg. 2020;68:716–24.CrossRef Darling GE. Lymph node assessment in early stage non-small cell lung cancer lymph node dissection or sampling? Gen Thorac Cardiovasc Surg. 2020;68:716–24.CrossRef
23.
go back to reference Lee AY, Choi SJ, Jung KP, Park JS, Lee SM, Bae SK. Characteristics of metastatic mediastinal lymph nodes of non-small cell lung cancer on preoperative F-18 FDG PET/CT. Nucl Med Mol Imaging. 2010;2014(48):41–6. Lee AY, Choi SJ, Jung KP, Park JS, Lee SM, Bae SK. Characteristics of metastatic mediastinal lymph nodes of non-small cell lung cancer on preoperative F-18 FDG PET/CT. Nucl Med Mol Imaging. 2010;2014(48):41–6.
24.
go back to reference Xue J, Zheng J, Guo H, Wang X, Han A. Predictive value of 18(F)-fluorodeoxyglucose positron emission tomography—computed tomography compared to postoperative pathological findings for patients with non-small-cell lung cancer. Mol Clin Oncol. 2015;3:109–14.CrossRef Xue J, Zheng J, Guo H, Wang X, Han A. Predictive value of 18(F)-fluorodeoxyglucose positron emission tomography—computed tomography compared to postoperative pathological findings for patients with non-small-cell lung cancer. Mol Clin Oncol. 2015;3:109–14.CrossRef
25.
go back to reference Zhang Y, Elam Y, Hall P, Williams H, Pucar D, Patel V. The role of fluorodeoxy-D-glucose positron emission tomography/computed tomography in nodal staging of nonsmall cell lung cancer in sequential surgical algorithm. World J Nucl Med. 2017;16:281–5.CrossRef Zhang Y, Elam Y, Hall P, Williams H, Pucar D, Patel V. The role of fluorodeoxy-D-glucose positron emission tomography/computed tomography in nodal staging of nonsmall cell lung cancer in sequential surgical algorithm. World J Nucl Med. 2017;16:281–5.CrossRef
26.
go back to reference Cheng G. Non-small-cell lung cancer PET imaging beyond F18 fluorodeoxyglucose. PET Clin. 2018;13:73–81.CrossRef Cheng G. Non-small-cell lung cancer PET imaging beyond F18 fluorodeoxyglucose. PET Clin. 2018;13:73–81.CrossRef
27.
go back to reference Lapa C, Lückerath K, Rudelius M, Schmid J-S, Schoene A, Schirbel A, et al. [68Ga]Pentixafor-PET/CT for imaging of chemokine receptor 4 expression in small cell lung cancer–initial experience. Oncotarget. 2016;7:9288–95.CrossRef Lapa C, Lückerath K, Rudelius M, Schmid J-S, Schoene A, Schirbel A, et al. [68Ga]Pentixafor-PET/CT for imaging of chemokine receptor 4 expression in small cell lung cancer–initial experience. Oncotarget. 2016;7:9288–95.CrossRef
28.
go back to reference Kratochwil C, Flechsig P, Lindner T, Abderrahim L, Altmann A, Mier W, et al. (68)Ga-FAPI PET/CT: tracer uptake in 28 different kinds of cancer. J Nucl Med. 2019;60:801–5.CrossRef Kratochwil C, Flechsig P, Lindner T, Abderrahim L, Altmann A, Mier W, et al. (68)Ga-FAPI PET/CT: tracer uptake in 28 different kinds of cancer. J Nucl Med. 2019;60:801–5.CrossRef
Metadata
Title
N-staging in large cell neuroendocrine carcinoma of the lung: diagnostic value of [18F]FDG PET/CT compared to the histopathology reference standard
Authors
Hubertus Hautzel
Yazan Alnajdawi
Wolfgang P. Fendler
Christoph Rischpler
Kaid Darwiche
Wilfried E. Eberhardt
Lale Umutlu
Dirk Theegarten
Martin Stuschke
Martin Schuler
Clemens Aigner
Ken Herrmann
Till Plönes
Publication date
01-12-2021
Publisher
Springer Berlin Heidelberg
Published in
EJNMMI Research / Issue 1/2021
Electronic ISSN: 2191-219X
DOI
https://doi.org/10.1186/s13550-021-00811-9

Other articles of this Issue 1/2021

EJNMMI Research 1/2021 Go to the issue